Cerdulatinib and its Impurities

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)). Reference standards of Cerdulatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.